Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Volume 25, Issue 6
  5. Article
Volume 25, Issue 6
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Breast cancer frequently occurs in women. Among the several types of breast cancers, almost 50% of breast cancers are caused by one or more gene mutations of the PI3K/mTOR/AKT pathway. Capivasertib, the first AKT inhibitor, was authorized by the US FDA on November 16, 2023. It is used for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with at least one alteration on In this short perspective, Capivasertib’s physicochemical properties, synthesis, mechanism of action, binding mode, pharmacokinetics, drug interaction studies, and treatment-emergent adverse events are discussed.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206360571241126080725
2024-12-04
2025-03-29

  • From This Site

    /content/journals/acamc/10.2174/0118715206360571241126080725
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BrayF. LaversanneM. SungH. FerlayJ. SiegelR.L. SoerjomataramI. JemalA. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202474322926310.3322/caac.21834 38572751
     [Google Scholar]
  2. DeS.K. Fundamental of cancer detection, treatment, and prevention.Wiley202215119110.1002/9783527838561.ch6
     [Google Scholar]
  3. MooT.A. SanfordR. DangC. MorrowM. Overview of breast cancer therapy.PET Clin.201813333935410.1016/j.cpet.2018.02.006 30100074
     [Google Scholar]
  4. TrayesK.P. CokenakesS.E.H. Breast Cancer Treatment.Am. Fam. Physician20211042171178 34383430
     [Google Scholar]
  5. SinghA. MishraR. MazumderA. Breast cancer and its therapeutic targets: A comprehensive review.Chem. Biol. Drug Des.20241031e1438410.1111/cbdd.14384 37919259
     [Google Scholar]
  6. BarileE. DeS.K. CarlsonC.B. ChenV. KnutzenC. Riel-MehanM. YangL. DahlR. ChiangG. PellecchiaM. Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway.J. Med. Chem.201053238368837510.1021/jm100825h 21062009
     [Google Scholar]
  7. IbanezK.R. HuangT.T. LeeJ.M. Combination therapy approach to overcome the resistance to PI3K pathway inhibitors in gynecological cancers.Cells20241312106410.3390/cells13121064 38920692
     [Google Scholar]
  8. ZhangH. JiangR. ZhuJ. SunK. HuangY. ZhouH. ZhengY. WangX. PI3K/AKT/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer.Breast Cancer202431453955110.1007/s12282‑024‑01567‑5 38630392
     [Google Scholar]
  9. BrowneI.M. AndréF. ChandarlapatyS. CareyL.A. TurnerN.C. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.Lancet Oncol.2024254e139e15110.1016/S1470‑2045(23)00676‑9 38547898
     [Google Scholar]
  10. WylaźM. KaczmarskaA. PajorD. HryniewickiM. GilD. Dulińska-LitewkaJ. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer.Biomed. Pharmacother.202316811567610.1016/j.biopha.2023.115676 37832401
     [Google Scholar]
  11. SelvamT.P. KarthickV. KumarP.V. AliM.A. Synthesis and structure-activity relationship study of 2-(substituted benzylidene)-7-(4-fluorophenyl)-5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one derivatives as anticancer agents.Drug Discov. Ther.20126419820410.5582/ddt.2012.v6.4.198 23006990
     [Google Scholar]
  12. BrowneI.M. OkinesA.F.C. Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogen-receptor-positive breast cancer.Cancers (Basel)20241612225910.3390/cancers16122259 38927964
     [Google Scholar]
  13. LuboffA.J. DeRemerD.L. Capivasertib: A novel AKT inhibitor approved for hormone-receptor-positive, HER-2-negative metastatic breast cancer.Ann. Pharmacother.202458121229123710.1177/10600280241241531 38566315
     [Google Scholar]
  14. López-KnowlesE. O’TooleS.A. McNeilC.M. MillarE.K.A. QiuM.R. CreaP. DalyR.J. MusgroveE.A. SutherlandR.L. PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality.Int. J. Cancer201012651121113110.1002/ijc.24831 19685490
     [Google Scholar]
  15. CsolleM.P. OomsL.M. PapaA. MitchellC.A. PTEN and other PtdIns(3,4,5)P3 lipid phosphatases in breast cancer.Int. J. Mol. Sci.20202123918910.3390/ijms21239189 33276499
     [Google Scholar]
  16. TurnerN.C. OliveiraM. HowellS.J. DalencF. CortesJ. Gomez MorenoH.L. HuX. JhaveriK. KrivorotkoP. LoiblS. Morales MurilloS. OkeraM. ParkY.H. SohnJ. ToiM. TokunagaE. YousefS. ZhukovaL. de BruinE.C. GrinstedL. SchiavonG. FoxleyA. RugoH.S. Capivasertib in hormone receptor–positive advanced breast cancer.N. Engl. J. Med.2023388222058207010.1056/NEJMoa2214131 37256976
     [Google Scholar]
  17. SmythL.M. TamuraK. OliveiraM. CiruelosE.M. MayerI.A. SablinM.P. BiganzoliL. AmbroseH.J. AshtonJ. BarnicleA. CashellD.D. CorcoranC. de BruinE.C. FoxleyA. HauserJ. LindemannJ.P.O. MaudsleyR. McEwenR. MoschettaM. PassM. RowlandsV. SchiavonG. BanerjiU. ScaltritiM. TaylorB.S. ChandarlapatyS. BaselgaJ. HymanD.M. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 E17K-mutant, er-positive metastatic breast cancer.Clin. Cancer Res.202026153947395710.1158/1078‑0432.CCR‑19‑3953 32312891
     [Google Scholar]
  18. SmythL.M. BatistG. Meric-BernstamF. KabosP. SpanggaardI. LluchA. JhaveriK. VargaA. WongA. SchramA.M. AmbroseH. CarrT.H. de BruinE.C. Salinas-SouzaC. FoxleyA. HauserJ. LindemannJ.P.O. MaudsleyR. McEwenR. MoschettaM. NikolaouM. SchiavonG. RazaviP. BanerjiU. BaselgaJ. HymanD.M. ChandarlapatyS. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.NPJ Breast Cancer2021714410.1038/s41523‑021‑00251‑7 33863913
     [Google Scholar]
  19. AndrikopoulouA. ChatzinikolaouS. PanourgiasE. KaparelouM. LiontosM. DimopoulosM.A. ZagouriF. The emerging role of capivasertib in breast cancer.Breast20226315716710.1016/j.breast.2022.03.018 35398754
     [Google Scholar]
  20. AddieM. BallardP. ButtarD. CrafterC. CurrieG. DaviesB.R. DebreczeniJ. DryH. DudleyP. GreenwoodR. JohnsonP.D. KettleJ.G. LaneC. LamontG. LeachA. LukeR.W.A. MorrisJ. OgilvieD. PageK. PassM. PearsonS. RustonL. Discovery of 4-Amino- N -[(1 S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7 H -pyrrolo[2,3- d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of akt kinases.J. Med. Chem.20135652059207310.1021/jm301762v 23394218
     [Google Scholar]
  21. WangY.T. YangP.C. ZhangY.F. SunJ.F. Synthesis and clinical application of new drugs approved by FDA in 2023.Eur. J. Med. Chem.202426511612410.1016/j.ejmech.2024.116124 38183778
     [Google Scholar]
  22. MillerC. WildM. ZhangZ. SommavillaR. ShanahanD. BaileyC. GränforsM. BraggR.A. DongJ. SidhuS. CullbergM. A Phase I study to determine the absolute bioavailability and absorption, distribution, metabolism, and excretion of capivasertib in healthy male participants.Drug Metab. Dispos.202452993994810.1124/dmd.124.001636
     [Google Scholar]
  23. Fernandez-TeruelC. CullbergM. EberleinC. BarryS.T. ZhouD. Population pharmacokinetics of capivasertib in patients with advanced or metastatic solid tumours.Clin. Pharmacokinet.20246381191120410.1007/s40262‑024‑01407‑x 39127854
     [Google Scholar]
  24. DeS.K. Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome.Front. Pharmacol.202415133743610.3389/fphar.2024.1337436 38410131
     [Google Scholar]
  25. RescignoP. PortaN. FinneranL. RiisnaesR. FigueiredoI. CarreiraS. FlohrP. MirandaS. BertanC. FerreiraA. CrespoM. RodriguesD.N. GurelB. NobesJ. CrabbS. MalikZ. RalphC. McGovernU. HoskinP. JonesR.J. BirtleA. GaleJ. SankeyP. JainS. McLarenD. ChadwickE. EspinasseA. HallE. de BonoJ. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.Eur. J. Cancer202420511410310.1016/j.ejca.2024.114103 38729054
     [Google Scholar]
  26. EberleinC. WilliamsonS.C. HopcroftL. RosS. MossJ.I. KerrJ. van WeerdenW.M. de BruinE.C. DunnS. WillisB. RossS.J. RooneyC. BarryS.T. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.Br. J. Cancer202413081377138710.1038/s41416‑024‑02614‑w 38396173
     [Google Scholar]
  27. CrabbS.J. GriffithsG. MarwoodE. DunkleyD. DownsN. MartinK. LightM. NortheyJ. WildingS. WhiteheadA. ShawE. BirtleA.J. BahlA. ElliottT. WestburyC. SundarS. RobinsonA. JagdevS. KumarS. RooneyC. Salinas-SouzaC. StephensC. KhooV. JonesR.J. Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: A randomized, placebo-controlled phase ii trial (ProCAID).J. Clin. Oncol.202139319020110.1200/JCO.20.01576 33326257
     [Google Scholar]
  28. YapT.A. KristeleitR. MichalareaV. PettittS.J. LimJ.S.J. CarreiraS. RodaD. MillerR. RiisnaesR. MirandaS. FigueiredoI. RodriguesD.N. WardS. MatthewsR. ParmarM. TurnerA. TunariuN. ChopraN. GevenslebenH. TurnerN.C. RuddleR. RaynaudF.I. DecordovaS. SwalesK.E. FinneranL. HallE. RugmanP. LindemannJ.P.O. FoxleyA. LordC.J. BanerjiU. PlummerR. BasuB. LopezJ.S. DrewY. de BonoJ.S. PhaseI. Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 - and non– BRCA1/2 -mutant cancers.Cancer Discov.202010101528154310.1158/2159‑8290.CD‑20‑0163 32532747
     [Google Scholar]
  29. WestinS.N. LabrieM. LittonJ.K. BlucherA. FangY. VellanoC.P. MarszalekJ.R. FengN. MaX. CreasonA. FellmanB. YuanY. LeeS. KimT.B. LiuJ. Chelariu-RaicuA. ChenT.H. KabilN. SolimanP.T. FrumovitzM. SchmelerK.M. JazaeriA. LuK.H. MurthyR. MeyerL.A. SunC.C. SoodA.K. ColemanR.L. MillsG.B. Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer.Clin. Cancer Res.202127236354636510.1158/1078‑0432.CCR‑21‑1656 34518313
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206360571241126080725
Loading
Capivasertib: First Approved AKT inhibitor for the Treatment of Patients with Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 25, 371 (2025); https://doi.org/10.2174/0118715206360571241126080725
/content/journals/acamc/10.2174/0118715206360571241126080725
/content/journals/acamc/10.2174/0118715206360571241126080725
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): AKT inhibitor; Breast cancer; capivasertib; drug metabolism; pharmacokinetics; PI3K inhibitor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test